China Resources Double-Crane Pharmaceutical (600062.SH) Subsidiary's Compound Potassium Hydrogen Phosphate Injection Obtains Drug Registration Certificate

China Resources Double-Crane Pharmaceutical (600062.SH) announced that recently, its wholly-owned subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. received the Drug Registration Certificate for Compound Potassium Hydrogen Phosphate Injection issued by the National Medical Products Administration. Compound Potassium Hydrogen Phosphate Injection serves as a phosphorus supplement: 1. When oral or enteral nutrition is impossible, insufficient, or contraindicated, it is used to correct hypophosphatemia in adult and pediatric patients. 2. When oral or enteral nutrition is impossible, insufficient, or contraindicated, it is used for parenteral nutrition in adult and pediatric patients.